Investigational Drug Information for Darapladib
✉ Email this page to a colleague
What is the development status for investigational drug Darapladib?
Darapladib is an investigational drug.
There have been 19 clinical trials for Darapladib.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 4th 2010.
The most common disease conditions in clinical trials are Atherosclerosis, Coronary Artery Disease, and Myocardial Ischemia. The leading clinical trial sponsors are GlaxoSmithKline, The TIMI Study Group, and National Heart, Lung, and Blood Institute (NHLBI).
Summary for Darapladib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 240 |
| WIPO Patent Applications | 150 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 3 (2010-02-04) |
| Vendors | 51 |
Recent Clinical Trials for Darapladib
| Title | Sponsor | Phase |
|---|---|---|
| Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM) | GlaxoSmithKline | Phase 1 |
| Darapladib China PK | GlaxoSmithKline | Phase 1 |
| Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects | GlaxoSmithKline | Phase 1 |
Clinical Trial Summary for Darapladib
Top disease conditions for Darapladib
Top clinical trial sponsors for Darapladib
US Patents for Darapladib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
